Edesa Biotech gains on FDA's 'fast track' tag for COVID treatment

Edesa Biotech

20/12/2022 16:25

** U.S.-listed shares of Edesa Biotech Inc  EDSA.O  rise
5.2% to 95 cents
    ** Co receives U.S. FDA's "fast track" designation for its
experimental monoclonal antibody, EB05, for treating COVID-19
patients with acute respiratory distress syndrome (ARDS)
    ** ARDS is a severe form of respiratory failure
characterized by widespread inflammatory injury to lungs
    ** A fast track designation facilitates development and
expedites review of therapies with the potential to treat a
serious condition 
    ** In September, data from co's mid-stage study showed
critically ill hospitalized COVID patients given EB05 plus
standard of care (SOC) treatment had an 84% reduction in risk of
dying when compared to placebo plus SOC at 28 days
    ** Including session moves, stock down ~83% YTD
 (Reporting by Raghav Mahobe)
 ((Raghav.Mahobe@thomsonreuters.com;))